A study published on July 1, 2026, in Clinical Gastroenterology and Hepatology by Cedars-Sinai researchers reveals that coffee consumption is significantly associated with a reduced risk of cirrhosis, liver cancer, and liver-related mortality. Analyzing data from 354,957 UK Biobank participants over a median of 13 years, the research utilized MRI scans and blood protein analysis to establish a biological link between coffee intake and improved liver health markers. The authors emphasize that while the findings are promising, they are observational and do not establish direct causation. The protective effects were observed in both caffeinated and decaffeinated coffee, suggesting that non-caffeine compounds play a crucial role in mitigating liver inflammation and scarring. The study highlights that moderate consumption, particularly three to four cups daily, provides the most significant health associations. The research provides molecular evidence by identifying specific blood proteins associated with healthy liver function that are elevated in coffee drinkers. These findings offer a strategic foundation for future clinical research aimed at isolating the specific bioactive compounds responsible for liver protection and understanding the underlying metabolic pathways involved in liver disease prevention. For practical application, the researchers advise that coffee should not replace established healthy habits such as maintaining a healthy weight, regular exercise, and limiting alcohol. Individuals with specific medical conditions, such as uncontrolled hypertension or heart rhythm disorders, should consult healthcare providers before increasing their coffee intake, as caffeine may pose risks for certain populations.
